Page last updated: 2024-10-24

verapamil and Dyslipidemia

verapamil has been researched along with Dyslipidemia in 2 studies

Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.

Research Excerpts

ExcerptRelevanceReference
"Verapamil treatment reduced the severity and number of lytic lesions in cardiomyocytes, induced considerable glycogen accumulation in the sarcoplasm and its sequestration, promoted normalization, and prevented pronounced decrease of the relative RyR2 mRNA and SERCA2a mRNA in rat myocardium."5.42Expression of ryanodine receptor mRNA and sarcoplasmic Ca²⁺-ATPase mRNA in the myocardium and intracellular reorganization of cardiomyocytes in dyslipidemia and during verapamil treatment. ( Klinnikova, MG; Lushnikova, EL; Nepomnyashchikh, LM; Pichigin, VI; Yuzhik, EI, 2015)
"Verapamil treatment reduced the severity and number of lytic lesions in cardiomyocytes, induced considerable glycogen accumulation in the sarcoplasm and its sequestration, promoted normalization, and prevented pronounced decrease of the relative RyR2 mRNA and SERCA2a mRNA in rat myocardium."1.42Expression of ryanodine receptor mRNA and sarcoplasmic Ca²⁺-ATPase mRNA in the myocardium and intracellular reorganization of cardiomyocytes in dyslipidemia and during verapamil treatment. ( Klinnikova, MG; Lushnikova, EL; Nepomnyashchikh, LM; Pichigin, VI; Yuzhik, EI, 2015)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yuzhik, EI1
Lushnikova, EL1
Klinnikova, MG1
Pichigin, VI1
Nepomnyashchikh, LM1
Halna du Fretay, X1
Blanchard-Lemoine, B1
Schnebert, B1
Viossat, J1

Other Studies

2 other studies available for verapamil and Dyslipidemia

ArticleYear
Expression of ryanodine receptor mRNA and sarcoplasmic Ca²⁺-ATPase mRNA in the myocardium and intracellular reorganization of cardiomyocytes in dyslipidemia and during verapamil treatment.
    Bulletin of experimental biology and medicine, 2015, Volume: 158, Issue:4

    Topics: Animals; Diet, Atherogenic; DNA Primers; Dyslipidemias; Male; Myocardium; Myocytes, Cardiac; Rats; R

2015
[Variant angina: what to think in 2011?].
    Annales de cardiologie et d'angeiologie, 2011, Volume: 60, Issue:6

    Topics: Adrenergic beta-Antagonists; Angina Pectoris, Variant; Coronary Angiography; Diagnosis, Differential

2011